IASLC

Meaningful survival boosts in POSEIDON trial of front-line durvalumab, tremelimumab, and chemo

Results show need to integrate sexual health into care, researcher says

Phase II trial supports neoadjuvant nivolumab plus chemotherapy

Overall survival benefit now demonstrated

Early phase results set the stage for KRAS/immune-targeted combo as potential first-line option

Large randomized study shows non-inferiority to lobectomy

Study finds minimal improvements in the early diagnosis of young patients with lung cancer

Early trials of DZD9008 demonstrated responses in over a third of patients

More than 90% disease control rate, hint of improved PFS in pilot trial

Response rate topped 50% in patients with EGFR wild-type tumors and high MET expression

Six-month improvement in overall survival with surgery plus chemotherapy versus chemo alone

LDCT associated with a 16% relative reduction in mortality versus no screening

Responses in 42% of EGFR group, limited activity in ALK-rearranged lung cancer

Atezolizumab add-on offers promising outcomes in phase I trial